Media stories about La Jolla Pharmaceutical (NASDAQ:LJPC) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.0776770546844 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- La Jolla: Red Flags And A Vastly Overestimated Market Create A Compelling Short (seekingalpha.com)
- Notable Thursday Option Activity: LJPC, PANW, MDCO – Nasdaq (nasdaq.com)
- La Jolla Pharmaceutical Company (LJPC) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- La Jolla Pharmaceutical (LJPC) vs. Catabasis Pharmaceuticals (CATB) Head-To-Head Review (americanbankingnews.com)
La Jolla Pharmaceutical (NASDAQ LJPC) traded down $1.43 during trading hours on Friday, hitting $33.81. 195,385 shares of the stock traded hands, compared to its average volume of 453,975. La Jolla Pharmaceutical has a 12 month low of $16.41 and a 12 month high of $39.28.
A number of research analysts have recently issued reports on LJPC shares. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, November 1st. Cowen and Company reiterated a “buy” rating and issued a $55.00 price objective on shares of La Jolla Pharmaceutical in a research note on Friday, October 27th. J P Morgan Chase & Co assumed coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They issued an “overweight” rating and a $36.00 price objective for the company. BidaskClub lowered shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $52.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact La Jolla Pharmaceutical (LJPC) Stock Price” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-la-jolla-pharmaceutical-ljpc-stock-price.html.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.